Stephen Jones, MD
Family Medicine · Rainbow City, ALNPI 1124069240
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 127 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 40.7% of the total. Reporting peaked in 2021 at $805 and has fallen 78.7% since, to $172 in 2025.
Across 127 payments — averaging $15.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$817
- Collegium Pharmaceutical, Inc.$242
- Biodelivery Sciences International, Inc.$127
- Scilex Pharmaceuticals Inc.$105
- AbbVie$75
- Idorsia Pharmaceuticals US Inc$74
- plus $568 from 18 others
What the payments were for
- Food & beverage$2,008100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 64 | $817 |
| Collegium Pharmaceutical, Inc. | 17 | $242 |
| Biodelivery Sciences International, Inc. | 4 | $127 |
| Scilex Pharmaceuticals Inc. | 6 | $105 |
| AbbVie | 4 | $75 |
| Idorsia Pharmaceuticals US Inc | 5 | $74 |
| Redhill Biopharma Inc. | 1 | $71 |
| GRT US Holding, Inc. | 2 | $57 |
| Indivior Inc. | 3 | $55 |
| Abbott | 3 | $54 |
| Emergent Biosolutions Inc. | 1 | $45 |
| AstraZeneca | 2 | $42 |
| Amgen | 2 | $41 |
| Novo Nordisk | 2 | $35 |
| Boston Scientific | 2 | $24 |
| Medtronic | 1 | $20 |
| Lundbeck LLC | 1 | $20 |
| Si-bone, Inc. | 1 | $20 |
| Baudax Bio Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $16 |
| Orexo US, Inc. | 1 | $14 |
| Bayer | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Almatica Pharma LLC | 1 | $11 |
How this compares
$2,008 in reported general payments places this provider in the 70th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RelistorMethylnaltrexone Bromide | 38 | $86,619 |
| Xtampza ErOxycodone Myristate | 128 | $77,101 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 2,436 | $61,697 |
| OxycontinOxycodone Hcl | 90 | $55,002 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,603 | $42,999 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 122 | $27,385 |
| Buprenorphine | 76 | $21,746 |
| LinzessLinaclotide | 25 | $12,931 |
| Gabapentin | 1,030 | $7,766 |
| Oxycodone Hcl | 382 | $7,725 |
| MovantikNaloxegol Oxalate | 18 | $7,035 |
| Morphine Sulfate ErMorphine Sulfate | 233 | $5,271 |
| Tizanidine Hcl | 589 | $5,117 |
| Fentanyl | 39 | $3,770 |
| Lidocaine | 54 | $3,746 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $817 | $86,61938 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $242 | $77,101128 claims |
| AbbVieLinzess | $75 | $12,93125 claims |
| Redhill Biopharma Inc.Movantik | $71 | $7,03518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Rainbow City
- Lashelle BarmoreBirmingham$486K
- Regina BenjaminBayou la Batre$222K
- Jonathan ParkerMuscle Shoals$214K
- Kathleen DupperHuntsville$210K
- Whitney TewHuntsville$114K
- Kelly HunterTuscaloosa$84K
- Daniel EnglertHuntsville$82K
- Joel LaughlinMobile$75K
- Ashleigh Butts-WilkersonMobile$54K
- Philip WilsonDothan$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.